Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib vs chemotherapy or pembrolizumab in FGFR-altered urothelial carcinoma
CTR20182097Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of erdafitinib in transitional cell carcinoma (TCC), sponsored by Janssen Pharmaceutical. Started Nov 2018; status: completed.
02
Drugs
erdafitinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20182097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182097.